Advanced Biomed Financials
| ADVB Stock | 0.24 0.01 2.08% |
Advanced Biomed Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 4.0E-4 | 4.0E-4 |
|
| |||||
| Current Ratio | 2.28 | 2.4 |
|
|
Investors should never underestimate Advanced Biomed's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Advanced Biomed's cash flow, debt, and profitability to make informed and accurate decisions about investing in Advanced Biomed Common.
Net Income |
|
Advanced | Select Account or Indicator | Build AI portfolio with Advanced Stock |
Understanding current and past Advanced Biomed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Advanced Biomed's financial statements are interrelated, with each one affecting the others. For example, an increase in Advanced Biomed's assets may result in an increase in income on the income statement.
Please note, the presentation of Advanced Biomed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Advanced Biomed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Advanced Biomed's management manipulating its earnings.
Advanced Biomed Stock Summary
Advanced Biomed competes with BioNexus Gene, Trinity Biotech, Ridgetech, Aptorum Group, and Beyond Air. Advanced Biomed is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US00752P1049 |
| Business Address | 122 East 42nd |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.advanbiomed.com |
Advanced Biomed Key Financial Ratios
| Return On Equity | -1.65 | ||||
| EBITDA | (90.81 K) | ||||
| Net Income | (101.52 K) | ||||
| Book Value Per Share | 0.16 X | ||||
| Market Capitalization | 6.55 M |
Advanced Biomed Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 6.7M | 4.6M | 4.5M | 6.5B | 7.5B | 7.9B | |
| Other Current Liab | 2.0M | 2.4M | 2.0M | 2.9B | 3.3B | 3.5B | |
| Net Debt | (4.3M) | (2.4M) | (2.5M) | (2.9B) | (2.6B) | (2.5B) | |
| Retained Earnings | (9.5M) | (13.2M) | (16.0M) | (19.2B) | (17.3B) | (16.4B) | |
| Accounts Payable | 762.2K | 632.8K | 620.5K | 21.7K | 19.5K | 18.5K | |
| Cash | 4.8M | 2.6M | 2.6M | 2.9B | 3.3B | 3.5B | |
| Net Receivables | 162.5K | 4.8K | 6.3K | 8.0K | 7.2K | 6.8K | |
| Other Current Assets | 221.8K | 158.9K | 443.1K | 3.1B | 3.6B | 3.8B | |
| Total Liab | 3.2M | 3.3M | 2.8M | 3.0B | 3.5B | 3.7B | |
| Total Current Assets | 5.0M | 2.8M | 3.1M | 6.0B | 6.9B | 7.3B | |
| Short Term Debt | 244.6K | 223.5K | 64.1K | 1.1M | 1.3M | 1.4M |
Advanced Biomed Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Gross Profit | (4.5K) | (11.9K) | (12.6K) | (10.7K) | (9.6K) | (10.1K) | |
| Operating Income | (84.0K) | (100.0K) | (79.8K) | (94.1K) | (108.2K) | (113.6K) | |
| Ebit | (142.4K) | (121.5K) | (87.4K) | (101.5K) | (116.8K) | (122.6K) | |
| Research Development | 57.3K | 45.0K | 27.6K | 28.3K | 25.5K | 24.2K | |
| Ebitda | (137.9K) | (109.6K) | (74.8K) | (90.8K) | (104.4K) | (109.7K) | |
| Cost Of Revenue | 4.5K | 11.9K | 12.6K | 10.7K | 12.3K | 9.2K | |
| Income Before Tax | (142.4K) | (121.5K) | (87.4K) | (101.5K) | (116.8K) | (122.6K) | |
| Net Income | (142.4K) | (121.5K) | (87.4K) | (101.5K) | (116.8K) | (122.6K) |
Advanced Biomed Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 4.7M | (2.2M) | (14.3K) | 19.0K | 17.1K | 16.3K | |
| Free Cash Flow | (2.1M) | (3.2M) | (2.2M) | (182.5K) | (209.8K) | (220.3K) | |
| Change In Working Capital | 1.5M | 253.7K | 256.3K | (90.7K) | (81.6K) | (77.5K) | |
| Begin Period Cash Flow | 65.9K | 4.8M | 2.6M | 80.4K | 92.4K | 87.8K | |
| Total Cashflows From Investing Activities | (1.1M) | (263.0K) | (74.1K) | (985.0) | (1.1K) | (1.2K) | |
| Depreciation | 126.6K | 365.2K | 399.6K | 10.7K | 12.3K | 11.7K | |
| Other Non Cash Items | 1.7M | 150.2K | (53.5K) | 2.9B | 3.4B | 3.5B | |
| Capital Expenditures | 1.3M | 212.5K | 74.1K | 985.0 | 886.5 | 842.18 | |
| Total Cash From Operating Activities | (741.5K) | (3.0M) | (2.1M) | (181.5K) | (163.3K) | (171.5K) | |
| Net Income | (4.0M) | (3.7M) | (2.8M) | (101.5K) | (116.8K) | (122.6K) | |
| Total Cash From Financing Activities | 6.1M | 458.1K | 1.9M | 184.9K | 166.4K | 158.1K | |
| End Period Cash Flow | 4.8M | 2.6M | 2.6M | 99.4K | 89.5K | 85.0K |
Advanced Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Advanced Biomed's current stock value. Our valuation model uses many indicators to compare Advanced Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Advanced Biomed competition to find correlations between indicators driving Advanced Biomed's intrinsic value. More Info.Advanced Biomed Common is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Advanced Biomed's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Advanced Biomed's earnings, one of the primary drivers of an investment's value.Most indicators from Advanced Biomed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Advanced Biomed Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Advanced Biomed Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Advanced Biomed's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to about 30 K, whereas Enterprise Value is forecasted to decline to about 33.4 M.
| 2022 | 2023 | 2025 | 2026 (projected) | Interest Income | 21.4K | 53.5K | 61.5K | 64.6K | Net Interest Income | 21.4K | 53.5K | 61.5K | 64.6K |
Advanced Biomed fundamental ratios Correlations
Click cells to compare fundamentals
Advanced Biomed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Advanced Biomed fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 6.7M | 4.6M | 4.5M | 6.5B | 7.5B | 7.9B | |
| Other Current Liab | 2.0M | 2.4M | 2.0M | 2.9B | 3.3B | 3.5B | |
| Net Debt | (4.3M) | (2.4M) | (2.5M) | (2.9B) | (2.6B) | (2.5B) | |
| Retained Earnings | (9.5M) | (13.2M) | (16.0M) | (19.2B) | (17.3B) | (16.4B) | |
| Accounts Payable | 762.2K | 632.8K | 620.5K | 21.7K | 19.5K | 18.5K | |
| Cash | 4.8M | 2.6M | 2.6M | 2.9B | 3.3B | 3.5B | |
| Net Receivables | 162.5K | 4.8K | 6.3K | 8.0K | 7.2K | 6.8K | |
| Other Current Assets | 221.8K | 158.9K | 443.1K | 3.1B | 3.6B | 3.8B | |
| Total Liab | 3.2M | 3.3M | 2.8M | 3.0B | 3.5B | 3.7B | |
| Total Current Assets | 5.0M | 2.8M | 3.1M | 6.0B | 6.9B | 7.3B | |
| Short Term Debt | 244.6K | 223.5K | 64.1K | 1.1M | 1.3M | 1.4M |
About Advanced Biomed Financials
What exactly are Advanced Biomed Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Advanced Biomed's income statement, its balance sheet, and the statement of cash flows. Potential Advanced Biomed investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Advanced Biomed investors may use each financial statement separately, they are all related. The changes in Advanced Biomed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Advanced Biomed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Today, most investors in Advanced Biomed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Advanced Biomed's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Advanced Biomed growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Advanced Biomed February 16, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Advanced Biomed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Advanced Biomed Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Advanced Biomed Common based on widely used predictive technical indicators. In general, we focus on analyzing Advanced Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Advanced Biomed's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 28.22 | |||
| Value At Risk | (9.68) | |||
| Potential Upside | 8.11 |
Complementary Tools for Advanced Stock analysis
When running Advanced Biomed's price analysis, check to measure Advanced Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Advanced Biomed is operating at the current time. Most of Advanced Biomed's value examination focuses on studying past and present price action to predict the probability of Advanced Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Advanced Biomed's price. Additionally, you may evaluate how the addition of Advanced Biomed to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |